Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Relapsed Chronic Lymphocytic Leukemia
NCT00006226Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2000
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in chronic lymphocytic leukemia (CLL), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 5 years. Started Sep 2000; status: completed.
02
Drugs
thalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00006226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006226.